iotaMotion Surpasses 1,000 Clinical Procedures Performed with iotaSOFT® --Defining a New Era in Cochlear Implant Surgery

• Fewer than 5% of eligible patients worldwide receive cochlear implants today
• Hearing loss is the largest modifiable risk factor for dementia, linked to approximately 8% of global cases — more than hypertension, obesity, smoking, or depression

ST. PAUL, Minn., Sept. 25, 2025 /PRNewswire/ -- iotaMotion, Inc., the leader in robotic-assisted insertion systems for cochlear implantation, today announced it surpassed 1,000 clinical procedures utilizing the iotaSOFT^® Insertion System. This milestone underscores growing adoption of the first and only FDA market authorized robotic-assisted cochlear implant insertion system in the United States. The system provides surgeons with enhanced precision, consistency and control to one of the most delicate steps in cochlear implant (CI) surgery.

Now in its second full year of commercialization, iotaSOFT has been adopted in more than 30 leading cochlear implant centers nationwide, as well as an active pre-market clinical study site in Zurich, Switzerland.

"Cochlear implantation is one of the most transformative surgeries in medicine, yet for decades this critical step, electrode array insertion, has relied solely on the limits of the human hand," said Mike Lobinsky, CEO of iotaMotion. "With iotaSOFT, we are advancing CI surgery beyond human capability. By standardizing insertion and expanding access to the latest technology, we are not only empowering surgeons but also breaking down patient barriers like fear of surgery, opening the door for millions who could benefit."

Closing the Hearing Loss Treatment Gap

According to the World Health Organization (WHO), more than 430 million people worldwide experience disabling hearing loss, including more than 60 million individuals with severe or greater impairment, the population most likely to benefit from cochlear implants. Yet adoption remains strikingly low, with fewer than 5% of eligible patients worldwide receiving an implant.

Research highlights several factors driving this gap, including fear of losing residual hearing, lack of awareness about candidacy, emotional hesitancy to give up natural hearing and unrealistic expectations of outcomes. Combined with low global implant uptake, these barriers leave millions untreated despite being clinically eligible.

At the same time, hearing loss has been identified as the largest modifiable risk factor for dementia, accounting for about 8% of global cases — more than hypertension, obesity, smoking, or depression, The Lancet reported in 2020.

The iotaSOFT Insertion System directly addresses these barriers and concerns by enabling electrode array advancement with robotic consistency and control beyond the human hand. Studies and surgeon feedback confirm the system reduces insertion force and variability, helping to reduce trauma, preserve delicate cochlear structures, and improve patient confidence.

A 2025 study in The Laryngoscope, titled Robotic-Assisted Electrode Array Insertion Improves Rates of Hearing Preservation, found that 85% of patients in the robotic-assisted insertion group maintained hearing preservation at one year, compared with 71% in the manual insertion group, according to Khan et al.

"The iotaSOFT System was developed with one clear goal: to provide enhanced control and precision during one of the most critical steps of cochlear implant surgery," said Marlan Hansen, MD, chief medical officer of iotaMotion. "Reaching 1,000 clinical procedures is an important inflection point for both our company and the broader CI field as we demonstrate the value of robotic-assisted approaches in preserving delicate structures of the cochlea."

Surgeons Report Improved Precision and Consistency

The iotaSOFT Insertion System has been integrated into both academic and private practice settings with consistently positive results.

• "This technology allows me to perform electrode array insertions with even greater precision and consistency, case after case," said Michael Seidman, MD, an otologic surgeon at AdventHealth Celebration in Florida. "iotaSOFT has become an integral part of my practice and offers real value in limiting inner ear trauma for my patients."
• "As our cochlear implant program nears its 100th iotaSOFT insertion, I've seen firsthand the benefits of a steady, controlled advancement of the electrode array," added Eric Kraus, MD, an otologic surgeon at Atrium Health Wake Forest Baptist. "The system brings a level of precision that's simply not possible with manual technique alone."

ST. PAUL, Minn., Sept. 25, 2025 /PRNewswire/ -- iotaMotion, Inc., the leader in robotic-assisted insertion systems for cochlear implantation, today announced it surpassed 1,000 clinical procedures utilizing the iotaSOFT^® Insertion System. This milestone underscores growing adoption of the first and only FDA market authorized robotic-assisted cochlear implant insertion system in the United States. The system provides surgeons with enhanced precision, consistency and control to one of the most delicate steps in cochlear implant (CI) surgery.

Now in its second full year of commercialization, iotaSOFT has been adopted in more than 30 leading cochlear implant centers nationwide, as well as an active pre-market clinical study site in Zurich, Switzerland.

"Cochlear implantation is one of the most transformative surgeries in medicine, yet for decades this critical step, electrode array insertion, has relied solely on the limits of the human hand," said Mike Lobinsky, CEO of iotaMotion. "With iotaSOFT, we are advancing CI surgery beyond human capability. By standardizing insertion and expanding access to the latest technology, we are not only empowering surgeons but also breaking down patient barriers like fear of surgery, opening the door for millions who could benefit."

Closing the Hearing Loss Treatment Gap

According to the World Health Organization (WHO), more than 430 million people worldwide experience disabling hearing loss, including more than 60 million individuals with severe or greater impairment, the population most likely to benefit from cochlear implants. Yet adoption remains strikingly low, with fewer than 5% of eligible patients worldwide receiving an implant.

Research highlights several factors driving this gap, including fear of losing residual hearing, lack of awareness about candidacy, emotional hesitancy to give up natural hearing and unrealistic expectations of outcomes. Combined with low global implant uptake, these barriers leave millions untreated despite being clinically eligible.

At the same time, hearing loss has been identified as the largest modifiable risk factor for dementia, accounting for about 8% of global cases — more than hypertension, obesity, smoking, or depression, The Lancet reported in 2020.

The iotaSOFT Insertion System directly addresses these barriers and concerns by enabling electrode array advancement with robotic consistency and control beyond the human hand. Studies and surgeon feedback confirm the system reduces insertion force and variability, helping to reduce trauma, preserve delicate cochlear structures, and improve patient confidence.

A 2025 study in The Laryngoscope, titled Robotic-Assisted Electrode Array Insertion Improves Rates of Hearing Preservation, found that 85% of patients in the robotic-assisted insertion group maintained hearing preservation at one year, compared with 71% in the manual insertion group, according to Khan et al.

"The iotaSOFT System was developed with one clear goal: to provide enhanced control and precision during one of the most critical steps of cochlear implant surgery," said Marlan Hansen, MD, chief medical officer of iotaMotion. "Reaching 1,000 clinical procedures is an important inflection point for both our company and the broader CI field as we demonstrate the value of robotic-assisted approaches in preserving delicate structures of the cochlea."

Surgeons Report Improved Precision and Consistency

The iotaSOFT Insertion System has been integrated into both academic and private practice settings with consistently positive results.

As iotaMotion advances, the company remains committed to partnering with hearing health professionals worldwide to expand access to the benefits of robotic-assisted cochlear implantation.

About iotaMotion

iotaMotion, Inc. is a medical technology company based in St. Paul, Minnesota, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT^® Insertion System, is designed to preserve delicate intracochlear structures through a slow and consistent electrode array insertion. The system is commercially available in the United States and under clinical investigation in other global markets.

For more information, visit www.iotamotion.com or email pr@iotamotion.com. Follow us on LinkedIn, X, Facebook, YouTube.

Sources:

• World Health Organization. World Report on Hearing. Geneva: WHO; 2021.
• Hearing Health Collaborative. Current Estimates of Cochlear Implant Utilization in the United States. AdultHearing.com, 2023.
• Lancet Commission on Dementia Prevention, Intervention and Care. Lancet, 2020.
• Khan AM, et al. Robotic-Assisted Electrode Array Insertion Improves Rates of Hearing Preservation. The Laryngoscope, 2025.
• iotaMotion Bench Research (internal patient interviews and literature review), 2023; additional data on file.

Media Contact:
Holly Windler
619.929.1275
holly.windler@gmail.com

Photo - https://mma.prnasia.com/media2/2781481/iotaMotion_Robotic_Assisted_Cochlear_Implant_Insertion_System.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/545464/IOTAMOTION_NEW.jpg?p=medium600 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **



iotaMotion Surpasses 1,000 Clinical Procedures Performed with iotaSOFT® --Defining a New Era in Cochlear Implant Surgery



iotaMotion Surpasses 1,000 Clinical Procedures Performed with iotaSOFT® --Defining a New Era in Cochlear Implant Surgery

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: